Evaluating the Usability of the Product Kinder System Trial, Home Based Hormone for In-Vitro Fertilization (IVF) Monitoring System.

Fertility Disorders Clinical Trial

Official title:

A Pilot Study: A Prospective, Longitudinal, Observational Study, Evaluating the Usability of the Product Kinder System Trial, Home Based Hormone for In-Vitro Fertilization (IVF) Monitoring System.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05634850
• Other study ID #: 470_1036
• Status: Recruiting
• Start date: September 9, 2022
• Est. completion date: June 9, 2023

Study information

• Verified date: November 2022
• Source: Planet Innovation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In-vitro fertilisation (IVF) treatment involves women undergoing hormone stimulation (drug dosing) to produce more oocytes (eggs) to increase their chances of fertilisation. The information that IVF clinicians currently collect on a woman's hormonal response to IVF drug dosing comes from in-clinic blood testing. This requires patients to make a visit to the IVF clinic every few days to have the blood samples taken. The blood is then analysed in a laboratory for the hormone levels and the results are then sent back to the clinic. This monitoring process of frequent onsite visits and blood draws can often be quite inconvenient and disruptive for patients.

This observational study will assess a non-invasive in vitro diagnostic (IVD) device for measuring the common fertility hormones in urine. The test system is for use by both healthcare professionals in a clinical setting and nonprofessionals in a home care setting under the guidance of a health care professional. This study will provide pilot data on the usability of the IVD device from the intended end users as well as the correlation of urinary metabolite levels as measured by the IVD device and the serum concentration as measured by blood analysers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: June 9, 2023
• Est. primary completion date: June 9, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 30 Years to 40 Years

Eligibility

Inclusion Criteria:

• Women undergoing controlled ovarian stimulation treatment

• 30 to 40 years old (inclusive)

• Willingness to comply with study procedures for collection and testing of urine

Exclusion Criteria:

• Illiterate in English

• No access to smart phone that is compatible with App and/or is not connected to the internet

• Patients who are diabetic (Type I and Type II), have insulin resistance or a renal/liver disorder

• Patients who have taken oral contraceptives up to 4 days before the first stimulation day of the cycle

Related Conditions & MeSH terms

• Fertility Disorders

Intervention

Device:
• Kinder
Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.

Locations

Country	Name	City	State
Singapore	National University Hospital	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
Planet Innovation

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the usability of Kinder by patients undergoing controlled ovarian stimulation cycle	Patients will perform tests with the Kinder system and complete a usability questionnaire on their experience.	A single controlled ovarian stimulation cycle, typically up to 20 days
Primary	Correlation of fertility hormone serum and urinary metabolites	Correlation of E2, P4 and LH and their urinary metabolites (E1-3G, PdG and LH)	A single controlled ovarian stimulation cycle, typically up to 20 days